Cargando…

Genetic characterization of Polish ccRCC patients: somatic mutation analysis of PBRM1, BAP1 and KDMC5, genomic SNP array analysis in tumor biopsy and preliminary results of chromosome aberrations analysis in plasma cell free DNA

BACKGROUND: Mutation analysis and cytogenetic testing in clear cell renal cell carcinoma (ccRCC) is not yet implemented in a routine diagnostics of ccRCC. MATERIAL AND METHODS: We characterized the chromosomal alterations in 83 ccRCC tumors from Polish patients using whole genome SNP genotyping assa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kluzek, Katarzyna, Srebniak, Malgorzata I., Majer, Weronika, Ida, Agnieszka, Milecki, Tomasz, Huminska, Kinga, van der Helm, Robert M., Silesian, Adrian, Wrzesinski, Tomasz M., Wojciechowicz, Jacek, Beverloo, Berna H., Kwias, Zbigniew, Bluyssen, Hans A.R., Wesoly, Joanna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2017
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5438672/ https://www.ncbi.nlm.nih.gov/pubmed/28212566 http://dx.doi.org/10.18632/oncotarget.15331

Ejemplares similares

Identification of RCC Subtype-Specific microRNAs–Meta-Analysis of High-Throughput RCC Tumor microRNA Expression Data
por: Kajdasz, Arkadiusz, et al.
Publicado: (2021)

Expression of pre-selected TMEMs with predicted ER localization as potential classifiers of ccRCC tumors
por: Wrzesiński, Tomasz, et al.
Publicado: (2015)

FUT11 as a potential biomarker of clear cell renal cell carcinoma progression based on meta-analysis of gene expression data
por: Zodro, Elżbieta, et al.
Publicado: (2013)

Potential Approaches and Recent Advances in Biomarker Discovery in Clear-Cell Renal Cell Carcinoma
por: Majer, Weronika, et al.
Publicado: (2015)

Data supporting the roles of BAP1, STING, and IFN-β in ISGF3 activation in ccRCC
por: Langbein, Lauren E., et al.
Publicado: (2022)

An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC)
por: Wang, Yuanyuan, et al.
Publicado: (2016)

Untangling ccRCC prognosis with SLINKY
por: Reinfeld, Bradley I., et al.
Publicado: (2017)

Erratum to: An integrative genomics approach for identifying novel functional consequences of PBRM1 truncated mutations in clear cell renal cell carcinoma (ccRCC)
por: Wang, Yuanyuan, et al.
Publicado: (2016)

Bioinformatics Analysis of Prognostic Value of SPC24 in ccRCC and Pan-Cancer
por: Zhang, Jipeng, et al.
Publicado: (2022)

Functional and translational consequences of immunometabolic coevolution in ccRCC
por: Reznik, Ed, et al.
Publicado: (2023)

CD44 Is Associated with Poor Prognosis of ccRCC and Facilitates ccRCC Cell Migration and Invasion through HAS1/MMP9
por: Du, Tan, et al.
Publicado: (2023)

The epigenetic landscape of clear-cell renal cell carcinoma
por: Kluzek, Katarzyna, et al.
Publicado: (2015)

Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC
por: Ibragimova, Ilsiya, et al.
Publicado: (2013)

Clinical Benefit of Niraparib to TKI/mTORi-Resistance Metastatic ccRCC With BAP1-Frame Shift Mutation: Case Report and Literature Review
por: Lian, Bi-Jun, et al.
Publicado: (2022)

Pivotal biomarker expression and drug screening in advanced ccRCC
por: Xiao, Wen, et al.
Publicado: (2020)

SDHB Suppresses the Tumorigenesis and Development of ccRCC by Inhibiting Glycolysis
por: Fang, Zhiyu, et al.
Publicado: (2021)

Identification of key genes of the ccRCC subtype with poor prognosis
por: Puzanov, Grigory Andreevich
Publicado: (2022)

MT1X is an oncogene and indicates prognosis in ccRCC
por: Ding, Yanpeng, et al.
Publicado: (2022)

Cuproptosis in ccRCC: key player in therapeutic and prognostic targets
por: Lv, Yang, et al.
Publicado: (2023)

Integrative Analysis of DNA Methylation Identified 12 Signature Genes Specific to Metastatic ccRCC
por: Qian, Siwei, et al.
Publicado: (2020)

Integrative -omics and HLA-ligandomics analysis to identify novel drug targets for ccRCC immunotherapy
por: Reustle, Anna, et al.
Publicado: (2020)

The use of luteinizing hormone-releasing hormone analogues is still an indispensable element of therapy in castrate-resistant prostate cancer
por: Milecki, Tomasz, et al.
Publicado: (2014)

Hormone therapy in combination with radiotherapy in the treatment of prostate cancer: why and in which group of patients?
por: Milecki, Tomasz, et al.
Publicado: (2015)

Thioredoxin 1 (Trx1) is associated with poor prognosis in clear cell renal cell carcinoma (ccRCC): an example for the crucial role of redox signaling in ccRCC
por: Ribback, Silvia, et al.
Publicado: (2021)

Does the Urinary Proteome Reflect ccRCC Stage and Grade Progression?
por: Santorelli, Lucia, et al.
Publicado: (2021)

A multiomics disease progression signature of low-risk ccRCC
por: Strauss, Philipp, et al.
Publicado: (2022)

Knockdown of SETD2 promotes erastin-induced ferroptosis in ccRCC
por: Xue, Wei, et al.
Publicado: (2023)

Role of copper ionophore–induced death in immune microenvironment and clinical prognosis of ccRCC: An integrated analysis
por: Xia, Shunyao, et al.
Publicado: (2022)

The Variations’ in Genes Encoding TIM-3 and Its Ligand, Galectin-9, Influence on ccRCC Risk and Prognosis
por: Andrzejczak, Anna, et al.
Publicado: (2023)

Computational analysis of the mutations in BAP1, PBRM1 and SETD2 genes reveals the impaired molecular processes in renal cell carcinoma
por: Piva, Francesco, et al.
Publicado: (2015)

Analysis of dual energy spectral CT and pathological grading of clear cell renal cell carcinoma (ccRCC)
por: Wei, Jinyan, et al.
Publicado: (2018)

Bioinformatics analysis of KLF2 as a potential prognostic factor in ccRCC and association with epithelial-mesenchymal transition
por: Hu, Fangfang, et al.
Publicado: (2022)

Identification of genes of prognostic value in the ccRCC microenvironment from TCGA database
por: Wan, Bangbei, et al.
Publicado: (2020)

Identification of FDFT1 as a potential biomarker associated with ferroptosis in ccRCC
por: Huang, Ruizhen, et al.
Publicado: (2022)

Identification of AKI signatures and classification patterns in ccRCC based on machine learning
por: Wang, Li, et al.
Publicado: (2023)

Identification of key genes and pathways in human clear cell renal cell carcinoma (ccRCC) by co-expression analysis
por: Yuan, Lushun, et al.
Publicado: (2018)

Expression of micro-RNAs and genes related to angiogenesis in ccRCC and associations with tumor characteristics
por: Oliveira, Rita de Cássia, et al.
Publicado: (2017)

Transcription Factor and miRNA Interplays Can Manifest the Survival of ccRCC Patients
por: Qin, Shijie, et al.
Publicado: (2019)

In-Depth Mapping of the Urinary N-Glycoproteome: Distinct Signatures of ccRCC-related Progression
por: Santorelli, Lucia, et al.
Publicado: (2020)

LRG1 May Accelerate the Progression of ccRCC via the TGF-β Pathway
por: Hong, Quan, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_ncr68kgp251vvb9s7vk79on1cb